• 08 MAY 2017
    • 0

    PharmaCyte Biotech Updates IND Submission Process in Interview with Facet Life Sciences

    LAGUNA HILLS, Calif., May 08, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released an educational, interview-style Q&A article with Sarah DeMare, the Product Development Champion with Facet Life Sciences and U.S. Agent

    Read more →
    • 02 MAY 2017
    • 0

    PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors

    LAGUNA HILLS, Calif., May 02, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Thomas Yuen to its Board of Directors. Mr. Yuen’s stellar career is exemplified by his global

    Read more →
    • 19 APR 2017
    • 0

    PharmaCyte Biotech Receives the 2017 “Pipelines of Promise” Award from BIO International

    LAGUNA HILLS, CA, April 19, 2017 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has received the 2017 Buzz of BIO “Pipelines of Promise” award ahead of the 2017 BIO

    Read more →
    • 18 APR 2017
    • 0

    PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director

    LAGUNA HILLS, Calif., April 18, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today an interview-style Q&A article that discusses the company’s Cannabis Research Program with Mark L. Rabe, MD, the Director of

    Read more →
    • 10 APR 2017
    • 0

    PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations

    LAGUNA HILLS, Calif., April 10, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has made significant progress with PharmaCyte’s Cannabis Research Program.

    Read more →
    • 03 APR 2017
    • 0

    PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development

    LAGUNA HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Mark L. Rabe, MD, as Director of Cannabis Program Development. In his new role, Dr. Rabe

    Read more →
    • 22 MAR 2017
    • 0

    PharmaCyte Biotech Strengthens Protection of Cancer Therapy with Patent Filing

    LAGUNA HILLS, Calif., March 22, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) to protect

    Read more →
    • 17 MAR 2017
    • 0

    PharmaCyte Biotech CEO Addresses IND Submission Questions

    LAGUNA HILLS, Calif., March 17, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement by Chief Executive Officer Kenneth L. Waggoner that addresses the company’s position on releasing a date for

    Read more →
    • 13 MAR 2017
    • 0

    PharmaCyte Biotech Names Dr. Leonard Makowka as Senior Strategic Advisor

    LAGUNA HILLS, Calif., March 13, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has named Leonard Makowka, M.D., Ph.D. as Senior Strategic Advisor to the Chief Executive Officer and Board

    Read more →
    • 21 FEB 2017
    • 0

    PharmaCyte Biotech Discusses Patient Enrollment and TD2’s Role in Upcoming Clinical Trial

    LAGUNA HILLS, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, released today the third article in a series of Q&A articles that will be conducted with some of the key team

    Read more →